Lipid Modification to Reduce Cardiovascular Risk in Secondary Prevention Patients with Special Emphasis on PCSK9 Inhibitor Requirement: An Analysis Based on Delphi Panel Approach.

Kızılırmak, Pınar; Öngen, Zeki; Güleç, HASAN; Kayıkçıoğlu, Meral; Kılıçkap, MUSTAFA; Abacı, Adnan; Özer, Necla; Aydoğdu, Sinan; Temizhan, Ahmet; Yılmaz, Mehmet; Bozkurt, Engin; Dölek, Bilgen; Tokgözoğlu, Lale

doi:10.5543/tkda.2022.22367

Lipid Modification to Reduce Cardiovascular Risk in Secondary Prevention Patients with Special Emphasis on PCSK9 Inhibitor Requirement: An Analysis Based on Delphi Panel Approach.

Kızılırmak P., Öngen Z., Güleç S., Kayıkçıoğlu M., Kılıçkap M., Abacı A., ...Daha Fazla

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, cilt.50, ss.554-560, 2022 (ESCI, Scopus, TRDizin)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 50
Basım Tarihi: 2022
Doi Numarası: 10.5543/tkda.2022.22367
Dergi Adı: Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Central & Eastern European Academic Source (CEEAS), EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
Sayfa Sayıları: ss.554-560
Anahtar Kelimeler: Cardiovascular risk factors, Delphi, LDL-cholesterol, PCSK9 inhibitor, Turkey, LDL-C, METAANALYSIS, PREVALENCE, EVOLOCUMAB
Ankara Üniversitesi Adresli: Evet

Özet

Objective: The aim of this study is to analyze the low-density lipoprotein cholesterol-lowering therapies in secondary prevention patients by anatyzing their plasma low-density lipoprotein cholesterol levels. current treatment, considering their inadequate response to medications (as defined in current guidelines), and the requirement for a protein convertase subtilisin/kexin type 9 inhibitor.